|
|
|
|
Innovations in Stroke Prevention: An Update in Carotid Stenting
SOURCE: OR-Live, Inc.
2:55PM, July 10, 2008
Carotid stenting has been performed in the United States for over a decade and has been undergoing pivotal FDA device approval trials since 2000. Since 2004, 6 FDA-approved carotid stents have emerged for the subset of patients with severe carotid artery stenosis for whom endarterectomy, still the standard operation, carries a high surgical risk.
Throughout this period of innovation, the physicians at NewYork-Presbyterian Hospital, representing both Columbia University Medical Center and Weill Cornell Medical Center, have played a major role in the research and development of this technology. Those interested in remaining abreast of the latest developments in carotid stenting should view this webcast, which will show a challenging case and discuss future directions with innovators in the field.
The webcast will feature William A. Gray, MD, an interventional cardiologist and Director of Endovascular Care at NewYork-Presbyterian/Columbia University Medical Center, who was the national Principle Investigator of the ARCHeR (ACCULINK for Revascularization of Carotids in High Risk Patients) trial, proving the efficacy of filtered stenting in high-risk endarterectomy patients and ultimately resulting in the first carotid stent system ever approved in the US. His many research credits in this field include his work on the interventional management committee of the NIH- and NHLBI-sponsored trial, CREST (Carotid Revascularization Endarterectomy vs. Stenting Trial), which will randomize 2500 patients between stenting and endarterectomy in the US and Canada. CREST, which will be concluded sometime in 2008, is studying stenting in patients with standard surgical risk, a population that represents perhaps 70% of those undergoing endarterectomy.
For additional information visit
www.or-live.com/nyp/2103/index.cfm?cmpid=mediwire
|
|
|
|
|
|
We subscribe to the HONcode principles of the Health On the Net Foundation